The report provides a detailed analysis essential for establishing an Alogliptin production plant. It encompasses all critical aspects necessary for Alogliptin production, including the cost of Alogliptin production, Alogliptin plant cost, Alogliptin production costs, and the overall Alogliptin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Alogliptin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Alogliptin is an oral antihyperglycemic and selective inhibitor of dipeptidyl peptidase-4's (DPP-4) enzymatic activity, used to treat hyperglycemia in people with type-2 diabetes mellitus. It increases the level of incretin hormone, thereby increasing the secretion of insulin and decreasing the level of glucagon. It is recommended as a supplement to diet and exercise in individuals with type 2 diabetes mellitus to enhance glycemic control. Therefore, it finds its application in the pharmaceutical and medical industries.
The procurement of Alogliptin is influenced by its application in pharmaceutical and medical industries as an antihyperglycemic medication used for treating type-2 diabetes mellitus, which is a chronic disease increasingly diagnosed in adults and adolescents. Type-2 DB has a 2- to 4-fold increased risk of cardiovascular diseases and it is the seventh leading cause of death which increases the demand for drugs like Alogliptin. The aging population, not following a proper diet, and disturbed life cycles have also led to an increase in demand for the medication. It can be administrated with other antidiabetic drugs such as Metformin and pioglitazone, thus increasing the role of reducing blood glucose levels in patients and increasing its market demand.
It is available in oral form which makes it easy to take, therefore improving patient compliance. Easy access to Antidiabetic Drugs such as Alogliptin due to healthcare advancements and technological improvements, increases its market. It is known for showing fewer side effects, and therefore can be used for a longer time, making it safe. Overall, the industrial Alogliptin procurement is influenced by its applications in the pharmaceutical and medical industries as an antihyperglycemic medication, the increase in the cases of type-2 diabetes, the aging population, its use with other antidiabetic drugs, fewer side effects, healthcare and technological advancements, patient compliance, cost-effectiveness, research and development, logistics and distribution, and regulatory approvals.
Raw Material for Alogliptin Production
According to the Alogliptin production plant project report, the key raw material used in the production of Alogliptin includes 6-chloro-3-methyluracil.
Production Process of Alogliptin
The extensive Alogliptin production cost report consists of the following major industrial production process:
- Production from 6-chloro-3-methyluracil: The production process of Alogliptin involves a two-step process. It starts with the reaction between 6-Chloro-3-methyluracil and 2-(Bromomethyl)benzonitrile in the presence of toluene to form an intermediate. This intermediate is then coupled with 3-Aminopiperidine in the presence of NaHCO3 and n-Butanol to produce Alogliptin.
Alogliptin, commercially known as Nesina, is a white to off-white crystalline powder, having the molecular formula C18H21N5O2 and a molecular weight of 339.4 g/mol. It has a water solubility of 0.58 mg/mL. It dissolves in dimethyl sulfoxide, dissolves to some extent in ethanol, is very less soluble in octanol and isopropyl acetate, and is sparingly soluble in water and methanol. It remains stable when stored under suggested conditions. It is a 3-methyl-2,4-dioxo-3,4-dihydropyrimidine piperidine that has extra 2-cyanobenzyl and 3-aminopiperidin-1-yl groups (the R-enantiomer) at positions 1 and 2, respectively. It is a hypoglycemic agent as well as an inhibitor of dipeptidyl-peptidase IV used to treat hyperglycemia in individuals with type 2 diabetes mellitus.